Immunological aspects of cancer chemotherapy

被引：1338
作者：
Zitvogel, Laurence [1 ,2 ,3 ]
Apetoh, Lionel [1 ,3 ]
Ghiringhelli, Francois [1 ,2 ,3 ,4 ]
Kroemer, Guido [3 ,5 ]
机构：
[1] Inst Gustave Roussy, INSERM, U805, F-94805 Villejuif, France
[2] Inst Gustave Roussy, CIC BT507, F-94805 Villejuif, France
[3] Univ Paris 11, Fac Med Paris Sud, F-94276 Le Kremlin Bicetre, France
[4] Ctr Georges Francois Leclerc, F-21000 Dijon, France
[5] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France
来源：
NATURE REVIEWS IMMUNOLOGY | 2008年 / 8卷 / 01期
关键词：
D O I：
10.1038/nri2216
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Accumulating evidence indicates that the innate and adaptive immune systems make a crucial contribution to the antitumour effects of conventional chemotherapy-based and radiotherapy-based cancer treatments. Moreover, the molecular and cellular bases of the immunogenicity of cell death that is induced by cytotoxic agents are being progressively unravelled, challenging the guidelines that currently govern the development of anticancer drugs. Here, we review the immunological aspects of conventional cancer treatments and propose that future successes in the fight against cancer will rely on the development and clinical application of combined chemo- and immunotherapies.
引用
收藏
页码：59 / 73
页数：15
相关论文
共 124 条
[1]   Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].
Antonia, SJ ;
Mirza, N ;
Fricke, I ;
Chiappori, A ;
Thompson, P ;
Williams, N ;
Bepler, G ;
Simon, G ;
Janssen, W ;
Lee, JH ;
Menander, K ;
Chada, S ;
Gabrilovich, DI .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887
[2]   The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Criollo, Alfredo ;
Ortiz, Carla ;
Lidereau, Rosette ;
Mariette, Christophe ;
Chaput, Nathalie ;
Mira, Jean-Paul ;
Delaloge, Suzette ;
Andre, Fabrice ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
IMMUNOLOGICAL REVIEWS, 2007, 220 :47-59
[3]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[4]  
ARINAGA S, 1986, CANCER RES, V46, P4213
[5]   A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].
Arlen, PM ;
Gulley, JL ;
Parker, C ;
Skarupa, L ;
Pazdur, M ;
Panicali, D ;
Beetham, P ;
Tsang, KY ;
Grosenbach, DW ;
Feldman, J ;
Steinberg, SM ;
Jones, E ;
Chen, C ;
Marte, J ;
Schlom, J ;
Dahut, W .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269
[6]   Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma:: A prospectively German cooperative renal randomized trial of the carcinoma chemoimmunotherapy group (DGCIN) [J].
Atzpodien, J ;
Kirchner, H ;
Jonas, U ;
Bergmann, L ;
Schott, H ;
Heynemann, H ;
Fornara, P ;
Loening, SA ;
Roigas, J ;
Müller, SC ;
Bodenstein, H ;
Pomer, S ;
Metzner, B ;
Rebmann, U ;
Oberneder, R ;
Siebels, M ;
Wandert, T ;
Puchberger, T ;
Reitz, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1188-1194
[7]   Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination [J].
Badovinac, VP ;
Messingham, KAN ;
Jabbari, A ;
Haring, JS ;
Harty, JT .
NATURE MEDICINE, 2005, 11 (07) :748-756
[8]   Antivascular therapy of cancer: DMXAA [J].
Baguley, BC .
LANCET ONCOLOGY, 2003, 4 (03) :141-148
[9]   Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma [J].
Bajetta, E ;
Del Vecchio, M ;
Nova, P ;
Fusi, A ;
Daponte, A ;
Sertoli, MR ;
Queirolo, P ;
Taveggia, P ;
Bernengo, MG ;
Legha, SS ;
Formisano, B ;
Cascinelli, N .
ANNALS OF ONCOLOGY, 2006, 17 (04) :571-577
[10]  
BERD D, 1986, CANCER RES, V46, P2572
12345678910